格拉布里丁减轻了饮食诱导的糖尿病小鼠中的代谢障碍
Xiaoxue Yang1, Kaiyi Lai1, Jiayu Zhang1
1School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Phytotherapy research : PTR
|May 6, 2025
概括
甘的黄胺格拉布里丁 (GLD) 有效降低血糖,并改善2型糖尿病 (T2DM) 模型中的胰岛素敏感性. 它通过向参与葡萄糖和脂质代谢,线粒体功能和ER压力的关键途径来改善代谢功能障碍.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 2型糖尿病 (T2DM) 是一种复杂的代谢障碍,其特征是高血糖和胰岛素抵抗.
- 黄类药物,如甘中的格拉布里丁 (GLD),显示出对代谢疾病的潜在治疗益处.
- 了解T2DM中GLD的分子机制对于开发新型治疗策略至关重要.
研究的目的:
- 评估格拉布里丁 (GLD) 在改善2型糖尿病 (T2DM) 的治疗潜力.
- 在T2DM小鼠模型中阐明GLD作用的潜在机制.
主要方法:
- 一个T2DM小鼠模型被诱导使用高脂肪,高葡萄糖饮食.
- GLD是通过腹膜内注射以不同的剂量 (10,20,30毫克/体重) 进行的,其中甲胺作为阳性对照.
- 分析包括血糖,葡萄糖/胰岛素/酸盐耐受性测试,血清参数和葡萄糖/脂质代谢的分子标志物,线粒体功能和ER压力.
主要成果:
- 在T2DM小鼠中,GLD显著降低了禁食血糖水平,并改善了葡萄糖耐受性.
- GLD调节了葡萄糖生成和糖原合成途径,增强了葡萄糖平衡.
- GLD改善了胰岛素信号传递,减少了肝硬化症,增强了线粒体功能,并减轻了内分泌网膜压力.
结论:
- 格拉布里丁通过改善胰岛素敏感性和改善T2DM中的代谢障碍,显示出显著的抗糖尿病作用.
- GLD的多方面的机制包括调节葡萄糖和脂质代谢,增强线粒体功能,减少ER压力.
- 作为治疗2型糖尿病的潜在治疗剂,GLD具有前途.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Oral Hypoglycemic Agents: Glinides
108
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
108
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
105
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
105


